Evidence map›Paper›PMID 39322651›Full record

ArticleBone marrow transplantation2024

Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.

Masashi Nishikubo, Yoshimitsu Shimomura, Yosuke Nakaya, Akihito Shinohara, Naoyuki Uchida, Nobuyuki Takayama, Hikaru Kobayashi, Yasufumi Uehara, Jun Ishikawa, Kazuya Ishiwata and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Masashi NishikuboDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan. mnishi90@yahoo.co.jp.ORCID 0000-0002-6183-8910
Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.ORCID 0000-0003-1018-9508
Yosuke NakayaDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Akihito ShinoharaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.ORCID 0000-0002-5530-6133
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.ORCID 0000-0001-5952-5926
Nobuyuki TakayamaDepartment of Hematology, Kyorin University Faculty of Medicine, Mitaka-shi, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Yasufumi UeharaDepartment of Hematology, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Kazuya IshiwataDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Kajigaya, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Hideyuki NakazawaDepartment of Hematology and Medical Oncology, Shinshu University School of Medicine, Nagano, Japan.
Keisuke KataokaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Keio, Japan.
Junya KandaDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.ORCID 0000-0002-6704-3633
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume, Fukuoka, Japan.ORCID 0000-0003-4795-121X
Yasuji KozaiDepartment of Hematology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Yoshiko MatsuhashiDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Fumihiko IshimaruTechnical Department, Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan.
Sung-Won KimDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Shimotsuke, Tochigi, Japan.ORCID 0000-0002-4866-9307
Yoshiko AtsutaJapanese Data Center For Hematopoietic Cell Transplantation, Tokyo, Japan.ORCID 0000-0003-4404-2870
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.ORCID 0000-0003-0995-9405
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0002-2635-3395

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for relapsed or refractory non-Hodgkin lymphoma (R/R NHL). Allo-HSCT using post-transplant cyclophosphamide (PTCY-haplo) and umbilical cord blood transplantation (uCBT) are important donor options in the absence of matched related siblings. However, the data comparing these two donor sources in R/R NHL are limited. Using the Japanese nationwide transplantation registry data, we identified 857 patients with R/R NHL, including 169 patients who received PTCY-haplo and 688 who received uCBT for their first allo-HSCT between January 2013 and December 2021; 514 patients (60%) had B-cell lymphoma. More PTCY-haplo recipients received allo-HSCT using a reduced-intensity conditioning regimen in recent years. The 3-year overall survival (OS), progression-free survival (PFS), and graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) rates in the PTCY-haplo and uCBT groups were 44% versus 39% (P = 0.326), 34% versus 33% (P = 0.660), and 19% versus 23% (P = 0.910), respectively; the adjusted hazard ratios for OS, PFS, and GRFS were 0.89 (95% confidence interval: 0.69-1.15, P = 0.373), 0.98 (0.78-1.22, P = 0.852), and 0.92 (0.83-1.21, P = 0.920), respectively. The PTCY-haplo group showed faster neutrophil and platelet engraftment and a lower incidence of grade III-IV acute GVHD. Thus, PTCY-haplo and uCBT could serve as alternative donor sources in patients with R/R NHL.

Indexed as

Cord Blood Stem Cell TransplantationCyclophosphamideLymphoma, Non-HodgkinTransplantation, HaploidenticalAdolescentAdultAgedFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedTransplantation ConditioningYoung AdultCyclophosphamide

Identifiers

PMID39322651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.